* Iovance Biotherapeutics Inc is expected to show a rise in quarterly revenue when it reports results on November 7 for the period ending September 30 2024

* The San Carlos California-based company is expected to report a 11,373.0% increase in revenue to $53.808 million from $469 thousand a year ago, according to the mean estimate from 13 analysts, based on LSEG data.The company's guidance on August 8 2024, for the period ended September 30, was for revenue between $53.00 million and $55.00 million.

* ​LSEG's mean analyst estimate for Iovance Biotherapeutics Inc is for a loss of 30 cents per share.

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

* The mean earnings estimate of analysts was unchanged in the last three months. ​

* Wall Street's median 12-month price target for Iovance Biotherapeutics Inc is $24.00​, above​ its last closing price of $11.66. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI

ENDING ARTESTIMAT ESTIMATE MET, SE %

E® MISSED

Jun. 30 2024 -0.35 -0.35 -0.34 Beat 3.8

Mar. 31 2024 -0.42 -0.42 -0.42 Met 0.6

Dec. 31 2023 -0.43 -0.43 -0.45 Missed -4.3​

Sep. 30 2023 -0.46 -0.45 -0.46 Missed -1.3

​​Jun. -0.82 -0.80 -0.47 Beat 41

30 2023

Mar. 31 2023 -0.77 -0.64 -0.50 Beat 32.9​

Jan. 1 0001 -0.63 -0.64 -0.64 Met -0.4

Sep. 30 2022 -0.63 -0.64 -0.63 Beat 1.2

This summary was machine generated November 6 at 14:32 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)